Sanofi has announced a definitive agreement to acquire Vigil Neuroscience, Inc., a clinical-stage biotechnology company focused on novel treatments for neurodegenerative diseases. This acquisition supports Sanofi’s strategic emphasis on neurology and expands its early-stage pipeline with a promising therapeutic candidate for Alzheimer’s disease.
The key asset in the acquisition is VG-3927, an oral small molecule TREM2 agonist, set to enter Phase 2 clinical trials. TREM2 activation is believed to enhance the neuroprotective function of microglia, immune cells in the brain, by promoting phagocytosis, cell survival, and migration to areas of neuronal injury. These effects aim to address microglial dysfunction seen in Alzheimer’s disease, where debris accumulation and chronic inflammation contribute to neurodegeneration.
Dr. Houman Ashrafian, Head of R&D at Sanofi, noted, “This acquisition complements our capabilities in neurology and leverages our expertise in immunology. TREM2 is a compelling target for addressing the unmet needs of Alzheimer’s patients facing progressive cognitive decline with limited treatment options.”
Vigil’s CEO, Dr. Ivana Magovčević-Liebisch, added, “We are proud of our work advancing TREM2-based therapies and excited to accelerate VG-3927’s development with Sanofi’s extensive resources and global reach.”
Sanofi had previously invested $40 million in Vigil in June 2024, gaining exclusive negotiation rights for VG-3927. That strategic move has now culminated in a full acquisition, demonstrating Sanofi’s proactive approach in securing key assets to combat critical healthcare challenges.
Under the agreement, Sanofi will acquire all outstanding Vigil shares for $8 per share in cash, valuing the deal at approximately $470 million on a fully diluted basis. Shareholders will also receive a contingent value right (CVR) of $2 per share, payable upon VG-3927’s first commercial sale. The deal is expected to close in Q3 2025, pending shareholder and regulatory approvals.
Importantly, VGL101, Vigil’s second therapeutic program, is not included in the acquisition.
This acquisition underscores Sanofi’s continued investment in neurology and commitment to developing transformative therapies for Alzheimer’s and other neurodegenerative diseases.